CURRENT SURGICAL



The AI-powered future of surgery

We're building the defining surgical innovation company of this generation



$200B Market Cap (2025)

$13.1B Acquisition (2024)

$5.9B Acquisition (2019)

$2.25B Acquisition (2025)

$100B+ Market Cap Potential (2028+)

The future of surgery is microinvasive & autonomous

- With more than 50M surgeries per year in the US alone, surgery is a required modality

But right now there's a major technology gap

- Surgeon skill and experience limit outcomes
- Robotic systems are only available in major medical centers due to high cost and large size



CURRENT SURGICAL

We are pioneering AI + ultrasound to unlock autonomous microinvasive surgery

See precisely.
Cure precisely.

Ultrasound-based surgery that’s AI-driven and personalized.

Make every doctor an expert digital surgeon.

Each step is automated using our ability to ‘see and cure.’

Long-term defensible software and platform.

Can be rapidly adopted across all medical facilities, big or small.



CURRENT SURGICAL

We've achieved what others thought impossible

We moved fast at seed-stage to demonstrate all key components

Re-engineered the entire ultrasound technology stack

Ultrasound is the only technology that can simultaneously **see and treat** tissue with zero radiation — we are the first to bring both capabilities to a single device.

Unlocked microinvasive surgery using AI-guided energy delivery

We developed novel AI models from **proprietary training data**, enabling us to decode tissue properties to give doctors superhuman vision.

First product: ‘smart needle’ combining imaging and precision ablation to destroy tumors

See.

Real-time imaging shows diseased tissue and surrounding anatomy in 3D.

Treat.

Focused ultrasound precisely destroys the tumor, leaving healthy tissue intact.



Automate.

Software control and feedback allows any doctor to treat any solid tumor.

Inexpensive base platform & single-use smart-needle means easy adoption

~$50,000

Small footprint capital equipment

~$5,000

Per probe per procedure

Our platform will treat *any* solid tumor, *anywhere* in the body

$10B market

GO-TO-MARKET 2028

GTM indications (US)
- Liver
- Kidney

$200B market

2030

All solid tumors (US)
- Liver
- Kidney
- Breast
- Lung
- Pancreatic
- Prostate
- Musculoskeletal
- Thyroid
- Glioblastoma

$400B market

2035+

Oncology
- All solid tumors in all stages
- Biopsies
- Immunotherapies

Cardiac arrhythmias

Neural interventions
- Epilepsy
- Chronic pain
- Hypertension

The applications are endless

Automated interventions enable sea-change across core healthcare systems

Patient benefits	Targeted tumor destruction	Personalized immunotherapy planning (radiomics)	Cardiac treatments (atrial fibrillation)	Guided digital biopsy	Neural interventions (chronic pain, hypertension)
Clinical capabilities	Local tissue destruction	In-situ tissue imaging	Enhanced cellular uptake	Natural immune response trigger	Blood/brain barrier opening
Core features	Focal energy delivery	Microinvasive access	Navigation support		

First-mover advantage is insurmountable

Technical complexity creates patent fortress

Traditional players lack interdisciplinary expertise to replicate

Self-reinforcing dataset is proprietary

Competitors need years to build equivalent AI training sets

Clinical adoption locks out potential followers

First-on-the-scene creates strong switching costs

We've built the right team

Co-Founders



Al Mashal, PhD
Co-Founder & CEO

- Expert in energy-based surgical devices and minimally invasive surgery

Chris Wagner, PhD
Co-Founder & CTO

- Expert in surgical robotics and image-guided surgery

70+ Peer-reviewed publications
12 Patents | **11** Patent applications
90+ Years medical device development

Experts in surgical robotics, ultrasound, and deep learning

Fred Hamlin, PhD
Principal Mechanical Engineer



Julien Grondin, PhD
Principal Ultrasound Engineer

Heyuan Huang, PhD
Deep Learning Scientist



Nick Pett
Mechanical Engineer

Swathi Katakam
Biomedical Engineer

Matthieu Gros
Mechanical Engineer

Key Advisors

Daniel Hawkins
Former CEO, Shockwave ($13B acquisition)

Dr. Karun Sharma
Director of Interventional Radiology, GW University

Key accomplishments and future plans

Today — 2026-2027 — 2028+

SEED ($7.71M - raised)

- Tech stack proof of concept
- NSF & NIH SBIR grants ($756K)
- Animal study demonstration
- Technical team expansion
- FDA pathway confirmation
- Non-provisional patent

Achieved clinical embodiment

Looks-like, works-like

ACTIVE RAISE

- Preclinical studies with strategic sites and surgeons
- First in human use
- FDA preparation

First in human data

Product design & development complete

FUTURE RAISES

- FDA approval
- Clinical trials with strategic centers to accelerate growth
- Commercial scale-up

CURRENT SURGICAL

Contact

Al Mashal, PhD
al@currentsurgical.com

Chris Wagner, PhD
chris@currentsurgical.com

Our Partners

true Ventures
Johnson&Johnson
DRAPER
SciFounders
1517
FORTITUDE VENTURES
NIH
NSF
MEDTECH INNOVATOR